Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases
- Trial number:
- NCT05552469
- Trial phase:
- 1
- Study type:
- Targeted therapy
- Overall status:
- Not yet recruiting
Study start date
Scientific title
Summary
Key
Patients must be ≥ 18 years of age at the time of signing the informed consent form (ICF)The Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2 Patient must be a candidate for serial bone marrow aspirate and/or biopsy according to the institutions guidelines and must be willing to undergo a bone marrow aspirate.
Patients must have one of the following for eligibility into the study:
In dose optimization and expansion: IPSS-R defined very low, low or intermediate risk Myelodysplastic Syndrome (LR MDS) who failed to respond to or did not tolerate ESAs or luspatercept or HMAs and patients with del 5q who failed to respond to or did not tolerate lenalidomide; orIn dose optimization and expansion: IPSS-R defined very low, low or intermediate risk Chronic Myelomonocytic Leukemia (LR CMML) who failed to respond to or did not tolerate hydroxyurea or HMAs.
Key